Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Sarcoma 1Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 24Breast Neoplasms 15Carcinoma, Non-Small-Cell Lung 10Sarcoma 9Myelodysplastic Syndromes 9Stomach Neoplasms 8Multiple Myeloma 7Leukemia, Myelomonocytic, Chronic 7Myeloproliferative Disorders 6Uterine Cervical Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Lung Neoplasms 5Recurrence 4Prostatic Neoplasms 4Neoplasms 4Melanoma 4Leukemia, Monocytic, Acute 4Head and Neck Neoplasms 4Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Carcinoma, Hepatocellular 4Biliary Tract Neoplasms 4Advanced Solid Tumour 4Stomatitis 3Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Neuroendocrine Tumors 3Mucositis 3Leukemia, Myelomonocytic, Acute 3Cholangiocarcinoma 3

Interventions

Oxaliplatin 26Gemcitabine 22Fluorouracil 17Capecitabine 16Leucovorin 15pembrolizumab 14Docetaxel 14Cisplatin 13Bevacizumab 12Radiotherapy 8Paclitaxel 8Irinotecan 8Trastuzumab 7Pemetrexed 6Carboplatin 6130-nm albumin-bound paclitaxel 6durvalumab 5cemiplimab 5Erlotinib Hydrochloride 5Sunitinib 4Ramucirumab 4Metformin 4Gefitinib 4trastuzumab deruxtecan 3tislelizumab 3cabozantinib 3atezolizumab 3Taxes 3Sorafenib 3Panitumumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma × Injections × Clear all
NCT01125449 2025-05-18

Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease

Situs Cancer Research Center

Phase 2 Withdrawn
Plasma cellSarcoma

Adenocarcinoma, Carcinoma, Multiple Myeloma, Sarcoma, Desmoplastic Small Round Cell Tumor

NCT06942767 2025-04-27

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Qilu Pharmaceutical Co., Ltd.

Phase 2 Not yet recruiting
100 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡